Offer - Urjas Oil for just ₹ 1 X
Cefoprox CV 325 Tablet is a prescription medicine that is available as a Tablet. Cefoprox CV 325 Tablet also has some secondary and off-label uses. These are listed below.
The right dosage of Cefoprox CV 325 Tablet depends on the age, gender, and medical history of the patient. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. For detailed information on this, read through the dosage section.
While these are the most often observed Cefoprox CV 325 Tablet side effects, there are can be others also. These have been listed below. These side effects of Cefoprox CV 325 Tablet are usually temporary and subside with the completion of treatment. However, if these continue for a longer time, consult your doctor right away.
In addition, Cefoprox CV 325 Tablet's effect is Mild during pregnancy and Moderate for lactating mothers. Further, the section on Cefoprox CV 325 Tablet related warnings talks about Cefoprox CV 325 Tablet's effects on the liver, heart and kidney.
Cefoprox CV 325 Tablet is contraindicated in people with pre-existing medical conditions like Jaundice as it can result in adverse effects. The section on Cefoprox CV 325 Tablet contraindications lists all such conditions.
Besides this, Cefoprox CV 325 Tablet may also have severe interaction with some medicines. See below for a complete list.
In addition to the above precautions for Cefoprox CV 325 Tablet, it is important to know that it is safe while driving, and is habit-forming.
Cefoprox CV 325 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
Adult |
|
Geriatric |
|
Is the use of Cefoprox CV 325 Tablet safe for pregnant women?
Cefoprox CV has little to no side effects in pregnant women.
Is the use of Cefoprox CV 325 Tablet safe during breastfeeding?
Cefoprox CV can cause moderate side effects on breastfeeding women. If you feel its side effects, then stop taking this drug and consult your doctor. Take this medicine again only if your doctor advises to do so.
What is the effect of Cefoprox CV 325 Tablet on the Kidneys?
There can be some harmful effects on your kidneys after taking Cefoprox CV. If you witness any side effects, discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Cefoprox CV 325 Tablet on the Liver?
The liver can be affected by Cefoprox CV. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart Cefoprox CV only after medical advice.
What is the effect of Cefoprox CV 325 Tablet on the Heart?
Very few cases of side effects of Cefoprox CV on the heart have been reported.
If you are suffering from any of the following diseases, you should not take Cefoprox CV 325 Tablet unless your doctor advises you to do so -
Is this Cefoprox CV 325 Tablet habit forming or addictive?
Forming a habit of Cefoprox CV 325 Tablet has not been reported.
Interaction between Food and Cefoprox CV 325 Tablet
Taking Cefoprox CV 325 Tablet with food does not cause any problems.
Interaction between Alcohol and Cefoprox CV 325 Tablet
Due to lack of research, nothing can be said about side effects of consuming alcohol while taking Cefoprox CV 325 Tablet.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Vantin® (cefpodoxime proxetil )
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-311